Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alberto Bardelli

Showing results (211-220 of 259) with videos related to

Pageof 26
Sort By:
Genome Medicine|October 10, 2024
DNA demethylation triggers cell free DNA release in colorectal cancer cellsValeria Pessei, Marco Macagno, Elisa Mariella, et al.
Nature|June 23, 2012
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancerSandra Misale, Rona Yaeger, Sebastijan Hobor, et al.
Cancer Research|December 18, 2004
Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemiaMohamed Bentires-Alj, J Guillermo Paez, Frank S David, et al.
Cancer Discovery|April 28, 2025
Direct Inhibition of RAS Reveals the Features of Oncogenic Signaling Driven by RAS G12 and Q61 MutationsMichelangelo Marasco, Dinesh Kumar, Santiago Garcia Borrego, et al.
Cancer Discovery|April 10, 2021
Werner Helicase Is a Synthetic-Lethal Vulnerability in Mismatch Repair-Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy, and ImmunotherapyGabriele Picco, Chiara M Cattaneo, Esmée J van Vliet, et al.
Cancer Discovery|December 9, 2015
Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal CancerMariangela Russo, Giulia Siravegna, Lawrence S Blaszkowsky, et al.
Nature|November 30, 2017
Inactivation of DNA repair triggers neoantigen generation and impairs tumour growthGiovanni Germano, Simona Lamba, Giuseppe Rospo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 14, 2019
A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and OxaliplatinSabrina Arena, Giorgio Corti, Erika Durinikova, et al.
Cancer Discovery|May 16, 2012
A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancerAndrea Bertotti, Giorgia Migliardi, Francesco Galimi, et al.
Cell Reports. Medicine|August 26, 2025
Combining BET inhibition with SMAC mimetics restricts tumor growth and triggers immune surveillance in preclinical cancer modelsKsenija Slavic Obradovic, Florian Ebner, Artem V Artemov, et al.
Pageof 26

Showing results (211-220 of 259) with videos related to

Sort By:
Pageof 26
Genome Medicine|October 10, 2024
DNA demethylation triggers cell free DNA release in colorectal cancer cellsValeria Pessei, Marco Macagno, Elisa Mariella, et al.
Nature|June 23, 2012
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancerSandra Misale, Rona Yaeger, Sebastijan Hobor, et al.
Cancer Research|December 18, 2004
Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemiaMohamed Bentires-Alj, J Guillermo Paez, Frank S David, et al.
Cancer Discovery|April 28, 2025
Direct Inhibition of RAS Reveals the Features of Oncogenic Signaling Driven by RAS G12 and Q61 MutationsMichelangelo Marasco, Dinesh Kumar, Santiago Garcia Borrego, et al.
Cancer Discovery|April 10, 2021
Werner Helicase Is a Synthetic-Lethal Vulnerability in Mismatch Repair-Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy, and ImmunotherapyGabriele Picco, Chiara M Cattaneo, Esmée J van Vliet, et al.
Cancer Discovery|December 9, 2015
Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal CancerMariangela Russo, Giulia Siravegna, Lawrence S Blaszkowsky, et al.
Nature|November 30, 2017
Inactivation of DNA repair triggers neoantigen generation and impairs tumour growthGiovanni Germano, Simona Lamba, Giuseppe Rospo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 14, 2019
A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and OxaliplatinSabrina Arena, Giorgio Corti, Erika Durinikova, et al.
Cancer Discovery|May 16, 2012
A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancerAndrea Bertotti, Giorgia Migliardi, Francesco Galimi, et al.
Cell Reports. Medicine|August 26, 2025
Combining BET inhibition with SMAC mimetics restricts tumor growth and triggers immune surveillance in preclinical cancer modelsKsenija Slavic Obradovic, Florian Ebner, Artem V Artemov, et al.
Pageof 26